Search research articles
Contact Us
Filters
Showing results (71-80 of 148) with videos related to
Page
of 15
Sort By:
British Journal of Haematology
|
February 16, 2017
Upfront lower dose lenalidomide is less toxic and does not compromise efficacy for vulnerable patients with relapsed refractory multiple myeloma: final analysis of the phase II RevLite study
Hang Quach, Liam Fernyhough, Ross Henderson, et al.
Blood Advances
|
August 2, 2021
Incidence of central nervous system relapses in patients with DLBCL treated with lenalidomide as maintenance after R-CHOP
Sophie Bernard, Herve Ghesquieres, Rene-Olivier Casasnovas, et al.
American Journal of Hematology
|
March 23, 2021
WhiMSICAL: A global Waldenström's Macroglobulinemia patient-derived data registry capturing treatment and quality of life outcomes
Ibrahim Tohidi-Esfahani, Andrew Warden, Elena Malunis, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 26, 2015
Reply to G. Keramida et al
Sally F Barrington, N George Mikhaeel, Lale Kostakoglu, et al.
Blood
|
July 23, 2020
Zanubrutinib for the treatment of patients with Waldenström macroglobulinemia: 3 years of follow-up
Judith Trotman, Stephen Opat, David Gottlieb, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 13, 2014
Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group
Sally F Barrington, N George Mikhaeel, Lale Kostakoglu, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
July 14, 2022
Application of the Lugano Classification for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The PRoLoG Consensus Initiative (Part 1-Clinical)
Fabien Ricard, Bruce Cheson, Sally Barrington, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
July 14, 2022
Application of the Lugano Classification for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The PRoLoG Consensus Initiative (Part 2-Technical)
Fabien Ricard, Sally Barrington, Ron Korn, et al.
Scientific Reports
|
October 5, 2025
Expanded CD16<sup>+</sup>CD56<sup>+</sup>Granzyme B<sup>+</sup> NK like CD8<sup>+</sup> T cells an off target effect of bruton's tyrosine kinase inhibitors in Waldenström macroglobulinemia
Priyanka Hastak, Chansavath Phetsouphanh, Zong-Hong Zhang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 8, 2022
Improved Efficacy of Tafasitamab plus Lenalidomide versus Systemic Therapies for Relapsed/Refractory DLBCL: RE-MIND2, an Observational Retrospective Matched Cohort Study
Grzegorz S Nowakowski, Dok Hyun Yoon, Anthea Peters, et al.
Page
of 15
Search research articles
Search
Showing results (71-80 of 148) with videos related to
Sort By:
Page
of 15
British Journal of Haematology
|
February 16, 2017
Upfront lower dose lenalidomide is less toxic and does not compromise efficacy for vulnerable patients with relapsed refractory multiple myeloma: final analysis of the phase II RevLite study
Hang Quach, Liam Fernyhough, Ross Henderson, et al.
Blood Advances
|
August 2, 2021
Incidence of central nervous system relapses in patients with DLBCL treated with lenalidomide as maintenance after R-CHOP
Sophie Bernard, Herve Ghesquieres, Rene-Olivier Casasnovas, et al.
American Journal of Hematology
|
March 23, 2021
WhiMSICAL: A global Waldenström's Macroglobulinemia patient-derived data registry capturing treatment and quality of life outcomes
Ibrahim Tohidi-Esfahani, Andrew Warden, Elena Malunis, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 26, 2015
Reply to G. Keramida et al
Sally F Barrington, N George Mikhaeel, Lale Kostakoglu, et al.
Blood
|
July 23, 2020
Zanubrutinib for the treatment of patients with Waldenström macroglobulinemia: 3 years of follow-up
Judith Trotman, Stephen Opat, David Gottlieb, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 13, 2014
Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group
Sally F Barrington, N George Mikhaeel, Lale Kostakoglu, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
July 14, 2022
Application of the Lugano Classification for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The PRoLoG Consensus Initiative (Part 1-Clinical)
Fabien Ricard, Bruce Cheson, Sally Barrington, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
July 14, 2022
Application of the Lugano Classification for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The PRoLoG Consensus Initiative (Part 2-Technical)
Fabien Ricard, Sally Barrington, Ron Korn, et al.
Scientific Reports
|
October 5, 2025
Expanded CD16<sup>+</sup>CD56<sup>+</sup>Granzyme B<sup>+</sup> NK like CD8<sup>+</sup> T cells an off target effect of bruton's tyrosine kinase inhibitors in Waldenström macroglobulinemia
Priyanka Hastak, Chansavath Phetsouphanh, Zong-Hong Zhang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 8, 2022
Improved Efficacy of Tafasitamab plus Lenalidomide versus Systemic Therapies for Relapsed/Refractory DLBCL: RE-MIND2, an Observational Retrospective Matched Cohort Study
Grzegorz S Nowakowski, Dok Hyun Yoon, Anthea Peters, et al.
Page
of 15